Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
11.06. | H.C. Wainwright REITERATES Buy rating on GRI Bio stock | 2 | Investing.com | ||
23.05. | GRI Bio erweitert Kapazität für At-the-Market-Angebot | 2 | Investing.com Deutsch | ||
23.05. | GRI Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
22.05. | GRI Bio reports progress in pulmonary fibrosis treatment | 1 | Investing.com | ||
GRI BIO Aktie jetzt für 0€ handeln | |||||
22.05. | GRI Bio verzeichnet Fortschritte bei Behandlung von Lungenfibrose | 2 | Investing.com Deutsch | ||
22.05. | GRI Bio, Inc.: GRI Bio Presents Positive Pre-Clinical Data Demonstrating GRI-0621 Resolves Inflammation and Fibrosis in Bleomycin-Induced Fibrosis and Reiterates Promising Preliminary Phase 2a Clinical Results | 2 | GlobeNewswire (USA) | ||
21.05. | GRI Bio, Inc.: GRI Bio to Participate in the Virtual Investor Closing Bell Series | 1 | GlobeNewswire (USA) | ||
16.05. | GRI Bio, Inc.: GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase | 5 | GlobeNewswire (USA) | ||
15.05. | GRI Bio reports Q1 results | 2 | Seeking Alpha | ||
15.05. | GRI Bio reports positive early trial data for IPF treatment | 3 | Investing.com | ||
15.05. | GRI Bio, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
15.05. | GRI Bio, Inc.: GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025 | 159 | GlobeNewswire (Europe) | Positive interim 2-week safety and biomarker results from its ongoing Phase 2a study evaluating GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis ("IPF") Continued momentum with completed... ► Artikel lesen | |
15.05. | GRI Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
08.05. | GRI Bio reports positive interim biomarker data in IPF study | 1 | Investing.com | ||
08.05. | GRI Bio meldet positive Zwischenergebnisse bei Biomarkern in IPF-Studie | - | Investing.com Deutsch | ||
08.05. | GRI Bio, Inc.: GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis ("IPF") | 124 | GlobeNewswire (Europe) | The Independent Data Monitoring Committee (IDMC) has recommended to continue the study as planned as there are no safety concerns seen in the data reviewed Continued momentum with completed patient... ► Artikel lesen | |
07.05. | GRI Bio, Inc.: GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis ("IPF") | 177 | GlobeNewswire (Europe) | Enrollment completed for the 6-week interim analysis with 24 of the 36 planned patients now enrolled Company on track to report interim biomarker data from the first 12 patients imminently Completion... ► Artikel lesen | |
05.05. | GRI Bio, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
14.04. | H.C. Wainwright maintains Buy on GRI Bio stock, $10 target | 2 | Investing.com | ||
02.04. | GRI Bio, Inc.: GRI Bio Announces Closing of $5.0 Million Public Offering | 1 | GlobeNewswire (USA) |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
BIONTECH | 89,60 | -0,22 % | Biotech Report: Biontech rutschen ab; Sektor an der Wall Street leichter | (shareribs.com) Frankfurt / New York 23.06.2025 - Biotech-Aktien zeigen sich im deutschen Handel überwiegend leichter. Unter anderem sacken Biontech kräftig ab. Auch an der Wall Street bewegt sich der... ► Artikel lesen | |
EVOTEC | 7,160 | +4,04 % | BioNTech schluckt CureVac! Evotec und Vidac als nächstes? Kurstreiber Übernahme und Kaufempfehlung | Steht bei Vidac Pharma eine neue Kursexplosion bevor? Im vergangenen Herbst ging es um rund 200 % nach oben. Gestern gab es eine Kaufempfehlung. Die Analysten sehen bei der Biotech-Perle Vervielfachungspotenzial.... ► Artikel lesen | |
CUREVAC | 4,630 | -0,34 % | EQS-News: CureVac Announces Voting Results of General Meeting | Emittent / Herausgeber: CureVac
/ Schlagwort(e): Hauptversammlung
CureVac Announces Voting Results of General Meeting
24.06.2025 / 22:09 CET/CEST
Für den Inhalt der... ► Artikel lesen | |
AMGEN | 240,75 | +0,10 % | ROUNDUP/Aktien New York Schluss: Gewinne - 'Iran-Angriff eine Gesichtswahrung' | NEW YORK (dpa-AFX) - Der Nahost-Krieg hat am Montag die Richtung an den US-Börsen bestimmt. Die wichtigsten US-Indizes legten am Ende kräftig zu und erreichten kurz vor dem Handelsschluss Tageshöchststände.... ► Artikel lesen | |
PALATIN TECHNOLOGIES | 0,143 | 0,00 % | Palatin Technologies Q1 Net Loss Narrows On Lower Expenses | WASHINGTON (dpa-AFX) - Palatin Technologies, Inc. (PTNT.PK), a biopharmaceutical company, on Wednesday reported narrower net loss in its first quarter with sharply lower operating expenses.Palatin... ► Artikel lesen | |
BIOXXMED | 0,420 | 0,00 % | XETR DELETION OF INSTRUMENTS FROM XETRA - 31.03.2025 | The following instruments on Xetra do have their last trading day on 31.03.2025.Die folgenden Instrumente auf Xetra haben ihren letzten Handelstag am 31.03.2025.ISIN NameDE000A4BGGE4 bioXXmed AG ► Artikel lesen | |
VIVOSIM LABS | 1,220 | -100,00 % | VivoSim Labs, Inc.: VivoSim Announces Emergence from Stealth Mode To Provide Technologies for FDA Turn Away from Animal Models, $10B+ Market | SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- VivoSim Labs, Inc. (Nasdaq: VIVS) (the "Company") announced that it has emerged from stealth mode to dramatically impact drug discovery and development.... ► Artikel lesen | |
OCUGEN | 0,911 | +2,57 % | Ocugen, Inc.: Carisma Therapeutics and OrthoCellix Enter into Definitive Merger Agreement to Create Company Focused on Regenerative Cell Therapies for Orthopedic Diseases | Proposed reverse merger with OrthoCellix, a wholly-owned subsidiary of Ocugen, to create Nasdaq-listed, late clinical-stage regenerative cell therapy company with a first-in-class technology platform... ► Artikel lesen | |
SIRONA BIOCHEM | 0,037 | -100,00 % | Sirona Biochem gibt Finanzierung mittels Wandelschuldverschreibung bekannt | Vancouver, British Columbia, 22. April 2025 / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB: ZSB) (OTC: SRBCF) ("Sirona" oder das "Unternehmen") gibt eine nicht vermittelte Privatplatzierung... ► Artikel lesen | |
BIO-GATE | 0,970 | -2,51 % | Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts | Nürnberg (www.anleihencheck.de) - Bio-Gate beschließt Ausgabe einer Wandelschuldverschreibung unter Ausschluss des Bezugsrechts - AnleihenewsVorstand und Aufsichtsrat der Bio-Gate AG (ISIN DE000BGAG981/... ► Artikel lesen | |
DEFENCE THERAPEUTICS | 0,500 | +6,16 % | Defence Therapeutics Inc.: Defence Therapeutics Receives USPTO Allowance for Patent Application Covering Next-Gen ADC Technology | Montreal, Quebec--(Newsfile Corp. - June 9, 2025) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a leading biotechnology company specializing in drug... ► Artikel lesen | |
NUREXONE BIOLOGIC | 0,421 | -2,55 % | Biotech-Pick: Warum sie diese Aktie unbedingt auf dem Zettel haben sollten! | ||
VAXART | 0,475 | +3,53 % | Vaxart, Inc.: Vaxart Announces Preliminary Results of Annual Meeting of Stockholders | SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) ("Vaxart" or the "Company"), a clinical-stage biotechnology company developing a range of oral recombinant... ► Artikel lesen | |
IBIO | 0,730 | 0,00 % | iBio stock soars after amylin receptor antibody shows promising results | ||
BURCON NUTRASCIENCE | 2,340 | 0,00 % | Burcon NutraScience Corporation: Burcon Announces Fiscal 2025 Results and Reviews Operations | Vancouver, British Columbia--(Newsfile Corp. - June 25, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in plant-based protein... ► Artikel lesen |